NCT06408285View on ClinicalTrials.gov

A Study of TQC3927 Powder for Inhalation in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

August 19, 2024

Study Completion Date

August 19, 2024

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

TQC3927 powder for inhalation

TQC3927 is a targeted inhibitor.

DRUG

TQC3927 powder for inhalation placebo

TQC3927 powder for inhalation placebo contains no active substance.

Trial Locations (1)

100000

China Japan Friendship Hospital, Beijing

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY